151 related articles for article (PubMed ID: 23011823)
1. The selective expression of ret finger protein in endometrial cancer: can RFP be a marker of serous carcinomas?
Tezel GG; Ordulu Z; Hımmetoğlu C; Usubütün A
Turk Patoloji Derg; 2012; 28(3):213-9. PubMed ID: 23011823
[TBL] [Abstract][Full Text] [Related]
2. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium.
Al Kushi A; Lim P; Aquino-Parsons C; Gilks CB
Mod Pathol; 2002 Apr; 15(4):365-71. PubMed ID: 11950909
[TBL] [Abstract][Full Text] [Related]
3. Expression pattern of osteopontin in endometrial carcinoma: correlation with expression of the adhesion molecule CEACAM1.
Briese J; Schulte HM; Bamberger CM; Löning T; Bamberger AM
Int J Gynecol Pathol; 2006 Apr; 25(2):161-9. PubMed ID: 16633066
[TBL] [Abstract][Full Text] [Related]
4. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.
Zheng W; Yi X; Fadare O; Liang SX; Martel M; Schwartz PE; Jiang Z
Am J Surg Pathol; 2008 Feb; 32(2):304-15. PubMed ID: 18223334
[TBL] [Abstract][Full Text] [Related]
5. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses.
Lax SF; Kurman RJ
Verh Dtsch Ges Pathol; 1997; 81():228-32. PubMed ID: 9474874
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
[TBL] [Abstract][Full Text] [Related]
7. Beta-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype.
Schlosshauer PW; Ellenson LH; Soslow RA
Mod Pathol; 2002 Oct; 15(10):1032-7. PubMed ID: 12379748
[TBL] [Abstract][Full Text] [Related]
8. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases.
Yemelyanova A; Ji H; Shih IeM; Wang TL; Wu LS; Ronnett BM
Am J Surg Pathol; 2009 Oct; 33(10):1504-14. PubMed ID: 19623034
[TBL] [Abstract][Full Text] [Related]
9. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
Alvarez T; Miller E; Duska L; Oliva E
Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
[TBL] [Abstract][Full Text] [Related]
10. Serous versus high-grade endometrioid endometrial carcinoma: immunohistochemistry of RFP is not useful for differentiation.
Ussakli C; Usubutun A; Dincer N; Dolgun A; Bülbül D; Isikdogan Z; Haberal N; Ozen O; Tezel GG
Pol J Pathol; 2016; 67(3):221-227. PubMed ID: 28155970
[TBL] [Abstract][Full Text] [Related]
11. Opposite alterations of DNA methyltransferase gene expression in endometrioid and serous endometrial cancers.
Xiong Y; Dowdy SC; Xue A; Shujuan J; Eberhardt NL; Podratz KC; Jiang SW
Gynecol Oncol; 2005 Mar; 96(3):601-9. PubMed ID: 15721400
[TBL] [Abstract][Full Text] [Related]
12. Cytokeratin 19 expression in normal endometrium and in low-grade endometrioid adenocarcinoma of the endometrium.
Stewart CJ; Crook ML; Lacey J; Louwen K
Int J Gynecol Pathol; 2011 Sep; 30(5):484-91. PubMed ID: 21804393
[TBL] [Abstract][Full Text] [Related]
13. Claudin 1 differentiates endometrioid and serous papillary endometrial adenocarcinoma.
Sobel G; Németh J; Kiss A; Lotz G; Szabó I; Udvarhelyi N; Schaff Z; Páska C
Gynecol Oncol; 2006 Nov; 103(2):591-8. PubMed ID: 16797678
[TBL] [Abstract][Full Text] [Related]
14. [Endometrial carcinoma and precursor lesions].
Djordjević B; Stanojević Z
Srp Arh Celok Lek; 2007; 135(3-4):230-4. PubMed ID: 17642468
[TBL] [Abstract][Full Text] [Related]
15. Thyroid transcription factor-1 expression in endometrial and endocervical adenocarcinomas.
Siami K; McCluggage WG; Ordonez NG; Euscher ED; Malpica A; Sneige N; Silva EG; Deavers MT
Am J Surg Pathol; 2007 Nov; 31(11):1759-63. PubMed ID: 18059234
[TBL] [Abstract][Full Text] [Related]
16. Apoptosis and the expression of Bcl-2 and Bax in patients with endometrioid, clear cell, and serous carcinomas of the uterine endometrium.
Kokawa K; Shikone T; Otani T; Nishiyama R; Ishii Y; Yagi S; Yamoto M
Gynecol Oncol; 2001 May; 81(2):178-83. PubMed ID: 11330946
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical characterization of prototypical endometrial clear cell carcinoma--diagnostic utility of HNF-1β and oestrogen receptor.
Hoang LN; Han G; McConechy M; Lau S; Chow C; Gilks CB; Huntsman DG; Köbel M; Lee CH
Histopathology; 2014 Mar; 64(4):585-96. PubMed ID: 24103020
[TBL] [Abstract][Full Text] [Related]
18. IMP2 expression distinguishes endometrioid from serous endometrial adenocarcinomas.
Zhang L; Liu Y; Hao S; Woda BA; Lu D
Am J Surg Pathol; 2011 Jun; 35(6):868-72. PubMed ID: 21566514
[TBL] [Abstract][Full Text] [Related]
19. Expression of Ret finger protein correlates with outcomes in endometrial cancer.
Tsukamoto H; Kato T; Enomoto A; Nakamura N; Shimono Y; Jijiwa M; Asai N; Murakumo Y; Shibata K; Kikkawa F; Takahashi M
Cancer Sci; 2009 Oct; 100(10):1895-901. PubMed ID: 19650860
[TBL] [Abstract][Full Text] [Related]
20. PINCH protein expression in normal endometrium, atypical endometrial hyperplasia and endometrioid endometrial carcinoma.
Zhang HZ; Li XH; Zhang X; Zhang ZY; Meng YL; Xu SW; Zheng Y; Zhu ZL; Cui DS; Huang LX; Yan BY; Sun XF
Chemotherapy; 2010; 56(4):291-7. PubMed ID: 20714146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
